Get started
Author

Kai Shen

Observed names: K F Shen, K.-F. Shen, K.F. Shen, Shen, Kai
ORCID: 0009-0009-0439-635X
Observed ORCID: 0009-0009-0439-635X
OpenAlex ID: A5060934885
Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture
1989 · K.-F. Shen, S.M. Crain · Brain Research · 212
Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
1995 · S M Crain, K F Shen · Proceedings of the National Academy of Sciences · 204
Cholera toxin-A subunit blocks opioid excitatory effects of sensory neuron action potentials indicating mediation by Gs-linked opioid receptors
1990 · K.-F. Shen, S.M. Crain · Brain Research · 100
Organization of synaptic transmission in the mammalian solitary complex, studied in vitro.
1986 · J Champagnat, M Denavit-Saubié, et al. · The Journal of Physiology · 99
Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures
1988 · S.M. Crain, K.-F. Shen, et al. · Brain Research · 69
F11 neuroblastoma × DRG neuron hybrid cells express inhibitory μ- and δ-opioid receptors which increase voltage-dependent K+ currents upon activation
1992 · S.F. Fan, K.F. Shen, et al. · Brain Research · 52
Opioids at low concentration decrease openings of K+ channels in sensory ganglion neurons
1991 · S.-F. Fan, K.-F. Shen, et al. · Brain Research · 49
After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition.
1992 · S M Crain, K F Shen · Journal of Pharmacology and Experimental Therapeutics · 45
Dynorphin prolongs the action potential of mouse sensory ganglion neurons by decreasing a potassium conductance whereas another specific kappa opioid does so by increasing a calcium conductance
1990 · K.-F. Shen, S.M. Crain · Neuropharmacology · 34
μ and δ opioid agonists at low concentrations decrease voltage-dependent K+ currents in F11 neuroblastoma × DRG neuron hybrid cells via cholera toxin-sensitive receptors
1993 · S.F. Fan, K.F. Shen, et al. · Brain Research · 32
Opioids can evoke direct receptor-mediated excitatory as well as inhibitory effects on sensory neuron action potentials.
1990 · S M Crain, K F Shen · PubMed · 15
Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies
2024 · Yaru Yang, Hongyan Qiu, et al. · Alzheimer s Research & Therapy · 8
PDF
A Phase I Study to Evaluate the Relative Bioavailability, Pharmacodynamics, and Safety of a Single Subcutaneous Injection of Recaticimab at Three Different Sites in Healthy Chinese Subjects
2025 · Ying Wang, Yuanzhi Cheng, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 5
Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers
2025 · Xin Gao, Kai Shen, et al. · Drug Design Development and Therapy · 3
PDF
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
2025 · Chang Shu, Ying Wang, et al. · Clinical Pharmacokinetics · 3
HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: A first-in-human, phase 1 trial
2025 · Yi Xu, Fen Tian, et al. · Med · 3
Evaluation of the pharmacokinetic interactions of montmorillonite powder or loperamide on pyrotinib in healthy volunteers
2025 · Yike Wang, Dai Li, et al. · Frontiers in Pharmacology · 3
PDF
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
2024 · Xiaotong Hu, Hongda Lin, et al. · The Journal of Clinical Pharmacology · 3
Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR ‐1819 in healthy subjects: A randomized, controlled phase I study
2024 · Na Li, Sepehr Shakib, et al. · Clinical and Translational Science · 3
PDF
Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer
2024 · Peng Chen, Yanyan Zhang, et al. · CPT Pharmacometrics & Systems Pharmacology · 2
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study
2025 · Pingping Lin, Chenjing Wang, et al. · Expert Opinion on Investigational Drugs · 1
Physiologically‐Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients
2025 · Xinyue Zhang, Hao Xue, et al. · Pediatric Diabetes · 1
PDF
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist, in healthy men
2024 · Qi Shen, Lingzhi Li, et al. · Expert Opinion on Investigational Drugs · 1
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
2025 · Yue Fei, Zhihong Xie, et al. · Drug Design Development and Therapy
PDF
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study
2025 · Yue Fei, Zhihong Xie, et al. · Drug Design Development and Therapy
PDF
Works count: 33
Citation count: 947
H-index: 11
I10-index: 11
Year
Topic
Type